Slovenia

Slovenia is small, and the interesting number is not the total but the composition. On the bela recepta, the white self-pay prescription, six of the top ten best-selling medicines contain semaglutide or tirzepatide. Roughly 20% of all GLP-1 prescriptions in Slovenia are self-pay rather than reimbursed. The recorded value of white-prescription dispensing for these molecules in 2025 was around 2.2m euros and 2.4m euros across the two reported categories.

An earlier version of this page overstated this as a claim about the whole medicines market. The corrected statement is narrower and stronger: within the self-pay channel specifically, GLP-1s dominate, and that channel is a fifth of GLP-1 volume.

What that tells an operator is that Slovenian patients have already demonstrated willingness to pay full price through a legitimate pharmacy channel. The demand does not need to be created, only served.

The Zakon o lekarniški dejavnosti frames pharmacy provision as a javna služba, a public service. It is delivered principally through javni lekarniški zavodi, public pharmacy institutes founded by municipalities, with private provision possible only through a koncesija, a concession granted by the municipality to a qualified pharmacist under conditions including a demonstrated local need.

There is no route by which a foreign company acquires a Slovenian pharmacy chain. Concessions are personal to the pharmacist, limited in number and tied to municipal planning. Slovenia is the most closed ownership environment covered on this site alongside the German-speaking group, and for a different reason: not a guild rule, but a public-sector service model.

Any operator here works as a supplier or service provider to public institutes and concession holders, or not at all.

In June 2024, JAZMP, the national medicines agency, published a public warning about Shujsaj.com, a site selling weight-loss medicines to Slovenian consumers outside the licensed pharmacy channel.

The instructive part is what happened next: the site remains live. A public regulatory warning did not remove it. That is a realistic picture of enforcement capacity against offshore online sellers in a small market, and it cuts two ways. It means the grey channel is a real competitor that will not be cleared for you. It also means that a legitimate operator competing on trust, supply provenance and clinical supervision has a genuine differentiator, because the alternative is visibly unpoliced.

It should not be read as a signal that advertising or unlicensed supply is safe. JAZMP’s reach over a Slovenian-established entity is entirely different from its reach over an offshore website.

ZZZS, the health insurance institute, reimburses semaglutide for type 2 diabetes under indication conditions. Obesity carries no reimbursement, which is what produces the white-prescription segment described above.

Self-pay prices track the wider central European range, and the visible price sensitivity is high given the size of the grey channel. Verified pharmacy-level price data for Wegovy and Mounjaro in euros was not obtainable from a primary source.